Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.
J Infect Dis. 2010 Sep 15;202(6):894-8. doi: 10.1086/655780.
We quantified antibody responses to the hepatitis C virus (HCV) proteome that are associated with sustained virologic response (SVR) in human immunodeficiency virus (HIV)/HCV-coinfected patients treated with pegylated interferon and ribavirin. Analysis of pre- and posttreatment samples revealed significant decreases in the combined anti-core, anti-E1, and anti-NS4 HCV antibody titers in those with SVRs but not in those who experienced relapse or who did not respond. Furthermore, anti-HIV p24 antibody titers inversely correlated with treatment response. These results suggest that profiling anti-HCV antibody is useful for monitoring HCV therapy, especially in discriminating between those who experience relapse and those who have SVRs at 48 weeks.
我们定量分析了与人类免疫缺陷病毒(HIV)/丙型肝炎病毒(HCV)合并感染患者接受聚乙二醇干扰素和利巴韦林治疗后持续病毒学应答(SVR)相关的抗 HCV 蛋白组抗体反应。分析治疗前后的样本显示,SVR 患者的抗核心、抗 E1 和抗 NS4 HCV 抗体滴度显著下降,但复发或无应答者则没有这种下降。此外,抗 HIV p24 抗体滴度与治疗反应呈负相关。这些结果表明,分析抗 HCV 抗体对于监测 HCV 治疗,特别是在区分复发和 48 周时获得 SVR 的患者方面是有用的。